CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.77
+0.38 (+26.88%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.39
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume21,868
Market Cap44.288M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

    CURE Pharmaceutical (CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the related conditions. CURE will issue shares of its common stock to Therapix in exchange for the assets, and Therapix will as a result become a significant shareholder in CURE.

  • GlobeNewswirelast month

    CURE Pharmaceutical to Present on the Increased Bioavailability for Cannabinoids Due to New Delivery Technologies at O’Cannabiz Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that CEO Rob Davidson will be presenting at the O’Cannabiz Conference & Expo on June 9 at 2:50 PM ET in Toronto, Canada. Davidson will discuss “Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing Bioavailability of Cannabinoid Molecules” and will meet with investors at the conference. “The most common delivery methods for pharmaceutical cannabis such as capsules, tinctures and oils are extremely limited,” said Davidson.

  • GlobeNewswire2 months ago

    CURE Pharmaceutical to Showcase Company Growth at the 8th LD Micro Invitational

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4th at 4 PM PT/ 7 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. CEO Rob Davidson will be presenting and meeting with investors. “We are at a critical inflection point in our business with product launches and increased manufacturing capabilities,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery Production

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it received an investment of $500,000 from a strategic partner to advance its cannabinoid-based drug delivery product line. “This is an important step in building out our cannabinoid program, which targets therapies in a wide range of disease indications,” said Rob Davidson, CEO of CURE Pharmaceutical. Cannabinoids are chemical compounds found in plants, such as cannabis (phytocannabinoids), synthesized by cells of the human body (endocannabinoids) or synthesized in a laboratory (biosynthetic cannabinoids) that interact with the body’s endocannabinoid system.

  • Business Wire6 months ago

    CURE Pharmaceutical Adds New VP of Strategy and Business Development

    CURE Pharmaceutical , an innovative drug delivery and development company, today named Dr. Vered Gigi, Vice President of Strategy and Business Development. Dr.

  • Marketwired10 months ago

    CureDots(TM) Look to Redefine How Animal Clinical Trials Are Conducted -- CFN Media

    CFN Media Group , the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining CURE Pharmaceutical's recently developed CureDots™, ...

  • Marketwired11 months ago

    CFN Media Exclusive Interview: CURE Pharma Discusses Vision & Breakthrough Technology

    CFN Media Group , the leading agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview with CURE Pharmaceutical's executive team: Robert Davidson, CEO ...

  • Marketwired11 months ago

    CURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media

    CFN Media Group , the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing CURE Pharmaceutical Holding Corp. and its development ...

  • Marketwiredlast year

    Top 4 Companies Reinventing Cannabinoid Delivery -- CFN Media

    CFN Media Group , the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing the need for improved delivery technologies for cannabinoid-based ...